CMS Forecast: Big Drug Spending Growth, But Hospitals and Doctors Will Still Capture Most Healthcare Spending
Drug Channels - September 9, 2014
In 2013, prescription drug spending growth was again slower than the growth in total U.S. spending. Growth will accelerate as insurance coverage expands, the generic wave ends, and newer specialty drugs launch. By 2023, the U.S. will spend nearly $500 billion on drugs.
Big pharmacies knock on door of oil-rich North Dakota
Reuters - September 4, 2014
North Dakota's oil boom has fueled a construction bonanza for new supermarkets, restaurants and clothing stores. But try finding a Rite Aid, Walgreens or other national pharmacy chain in the state, the fastest-growing economy in the nation, and you'll be largely out of luck.
Nearly 90,000 ED visits annually linked to psychiatric drug events
Modern Healthcare - September 3, 2014
An estimated 267,000 patients visited an emergency department between 2009 and 2011 because of adverse drug events such as overdose, excessive sleepiness and head injuries associated with use of psychiatric prescriptions, a JAMA Psychiatry study finds. About 19% of the visits resulted in the patient being hospitalized.
Give Aspirin to All Pregnant Women at Risk of Preeclampsia: U.S. Experts
HealthDay News - September 8, 2014
Daily, low-dose regimen cuts odds of complication by 24 percent.
D.E.A. to Allow Return of Unused Pills to Pharmacies
New York Times - September 8, 2014
Concerned by rising rates of prescription drug abuse, the Drug Enforcement Administration announced Monday that it would permit consumers to return unused prescription medications like opioid painkillers to pharmacies.
Connecticut AG to FDA: Let Ranbaxy Sell a Generic Nexium, Already
Wall Street Journal - September 8, 2014
Will the FDA ever allow Ranbaxy Laboratories to sell a generic version of the Nexium heartburn pill?
Study questions drugs given to many with advanced Alzheimer’s
Boston Globe - September 8, 2014
More than half of patients with advanced dementia who are in the end stages of Alzheimer’s disease continue to receive drugs that have questionable benefits, such as medications to treat dementia and statins to lower their cholesterol levels, finds a new study from the University of Massachusetts Medical School in Worcester.
Study: EHRs Linked to Higher Revenue, Lower Patient Volume
iHealthBeat - September 2, 2014
Electronic health record implementation can result in reduced patient volume but can increase revenue over the long term, according to a study published in the Journal of the American Medical Informatics Association, Becker's Hospital Review's "Hospital CIO" reports
Popular cancer drug target implicated in cardiovascular defects
ScienceDaily - September 8, 2014
Researchers have discovered an unlikely relationship between CXCR7 -- a protein implicated in tumor growth and metastasis -- and adrenomedullin -- a hormone involved in cardiovascular health. Deleting CXCR7 allows adrenomedullin to run rampant, triggering the development of an enlarged heart and the overgrowth of the lymphatic vessels that traffic immune cells and fluids throughout the body.
Apple bans developers from selling HealthKit data to ad platforms
Mobi Health News - September 2, 2014
Late last week the Financial Times reported that Apple had modified its iOS developer license agreement, its rules for developers that create apps for its devices, to ban developers from selling health data collected by HealthKit.
Simeprevir in hepatitis C: Added benefit for certain patients
ScienceDaily - September 8, 2014
Certain patients with hepatitis genotype 1 infection -- without HIV infection -- have fewer symptoms or side effects. Probability and extent of added benefit vary, however.
Contact,
Kristin LaVitola
Marketing Director, PSG
Pharmaceutical Strategies Group (PSG)
Office: 972-244-8388
Email: KLavitola@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |